Photosensitivity reactions to vandetanib: Redevelopment after sequential treatment with docetaxel

Annals of Dermatology

Volumn 23, Issue SUPPL. 3, 2011, Pages

  Son, Young Min ^a   Roh, Joo Young ^a   Cho, Eun Kyung ^a   Lee, Jong Rok ^a  

^a Gachon University   (South Korea)

Author keywords

Docetaxel; Photosensitivity; Vandetanib

Indexed keywords

EID: 84863122521     PISSN: 10139087     EISSN: None     Source Type: Journal    
DOI: 10.5021/ad.2011.23.S3.S314     Document Type: Article

References (20)

1. James WD, Berger TG, Elston DM. Andrews' diseases of the skin. 10th ed. Philadelphia: WB Saunders, 2006:32-33.
2. Henry WL. Abnormal responses to ultraviolet radiation: photosensitivity induced by exogenous agents. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's dermatology in general medicine. 7th ed. New York: McGraw-Hill, 2008:828-834.
3. Hölzle E, Lehmann P, Neumann N. Phototoxic and photoallergic reactions. J Dtsch Dermatol Ges 2009;7:643-649.
4. Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007;6:431-443. (Pubitemid 351308172)
5. Racette AJ, Roenigk HH Jr, Hansen R, Mendelson D, Park A. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol 2005;52(5 Suppl 1):S81-85.
6. Heymach JV. ZD6474-clinical experience to date. Br J Cancer 2005;92(Suppl. 1):14-20.
7. Sathornsumetee S, Rich JN. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc) 2006;42:657-670. (Pubitemid 44901640)
8. Gridelli C, Maione P, Rossi A, Falanga M, Bareschino M, Schettino C, et al. New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Rev Anticancer Ther 2009;9:115-124.
9. Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs 2007;18:95-103. (Pubitemid 44967420)
10. Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009;13:49-59.
11. Lankerani L, Baron ED. Photosensitivity to exogenous agents. J Cutan Med Surg 2004;8:424-431. (Pubitemid 41414111)
12. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002;25:345-372. (Pubitemid 34634272)
13. González E, González S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 1996;35:871-885. (Pubitemid 26422109)
14. Elder D, Elenitsas R, Johnson B Jr, Murphy G, Xu Xl, Xu X. Lever's histopathology of the skin. 10th ed. Philadelphia: Lippincott-Raven, 2009:318-319.
15. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-1397. (Pubitemid 41158486)
16. Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002-1009. (Pubitemid 47181370)
17. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, et al. A randomized, double-blind, phase IIa dosefinding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008;3:386-393. (Pubitemid 351489479)
18. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005;11:3369-3376. (Pubitemid 40627889)
19. Chew L, Chuen VS. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 2009;15:29-34.
20. Kong HH, Fine HA, Stern JB, Turner ML. Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol 2009;145:923-925.